TEVA/MNTA—So much for Monness, Crespi, Hardt’s “modeling” Teva’s launch of generic Lovenox on April 1 (in their downgrade of MNTA on 2/14/11).
I previously ridiculed MCH’s model in #msg-59900603 and noted that an April 1 launch by Teva was quite impossible, but zipjet (being a notorious call writer :- )) opined that MCH’s report was a high-quality effort (#msg-59914929). This is what makes a market, folks!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.